@article {7761,
	title = {Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents},
	journal = {Leukemia Research},
	volume = {34},
	year = {2010},
	note = {Cited By :52Export Date: 21 February 2017},
	month = {2010},
	pages = {1395 - 1397},
	abstract = {The purpose of this analysis was to assess the effect of novel agent-based regimens on the improvement of renal impairment (RI) in newly diagnosed patients with multiple myeloma. Ninety-six consecutive patients with RI received conventional chemotherapy (CC)-based regimens (n= 32), IMiDs-based regimens (n= 47) or bortezomib-based regimens (n= 17) as frontline therapy. Improvement of RI was more frequent in patients treated with novel agents (79\% in IMiD- and 94\% in bortezomib-treated groups versus 59\% in CC-treated group; p= 0.02). Bortezomib-based regimens and CrCl > 30 ml/min at baseline independently correlated with a higher probability of at least renal partial response (PRrenal) and with a shorter time to PRrenal or better. Thus bortezomib-based regimens may be the preferred treatment for newly diagnosed myeloma patients with RI. {\textcopyright} 2010 Elsevier Ltd.},
	keywords = {bortezomib, Conventional chemotherapy, Lenalidomide, multiple myeloma, renal impairment, Thalidomide},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-77955985354\&doi=10.1016\%2fj.leukres.2010.04.024\&partnerID=40\&md5=4a9ac4cb8e98221b9efa08637738a58a},
	author = {Roussou, M. and Kastritis, E. and Christoulas, D. and Migkou, M. and Gavriatopoulou, M. and Grapsa, I. and Psimenou, E. and Gika, D. and Terpos, E. and Dimopoulos, M.A.}
}
